MEP21108A - Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation - Google Patents
Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammationInfo
- Publication number
- MEP21108A MEP21108A MEP-211/08A MEP21108A MEP21108A ME P21108 A MEP21108 A ME P21108A ME P21108 A MEP21108 A ME P21108A ME P21108 A MEP21108 A ME P21108A
- Authority
- ME
- Montenegro
- Prior art keywords
- modulators
- inflammation
- treatment
- furosemide
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54601104P | 2004-02-20 | 2004-02-20 | |
| PCT/US2005/004108 WO2005082350A1 (en) | 2004-02-20 | 2005-02-10 | Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP21108A true MEP21108A (en) | 2010-06-10 |
Family
ID=34910746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-211/08A MEP21108A (en) | 2004-02-20 | 2005-02-10 | Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7232811B2 (xx) |
| EP (1) | EP1718292A1 (xx) |
| JP (1) | JP2007523166A (xx) |
| KR (1) | KR20060127141A (xx) |
| CN (1) | CN1921845A (xx) |
| AR (1) | AR047747A1 (xx) |
| AU (1) | AU2005216879B2 (xx) |
| BR (1) | BRPI0506792A (xx) |
| CA (1) | CA2557444A1 (xx) |
| CR (1) | CR8528A (xx) |
| EC (1) | ECSP066777A (xx) |
| IL (1) | IL177086A (xx) |
| MA (1) | MA28373A1 (xx) |
| ME (1) | MEP21108A (xx) |
| MX (1) | MXPA06008612A (xx) |
| NO (1) | NO20064237L (xx) |
| NZ (1) | NZ548830A (xx) |
| RS (1) | RS20060473A (xx) |
| RU (1) | RU2006133540A (xx) |
| SG (1) | SG164305A1 (xx) |
| TN (1) | TNSN06234A1 (xx) |
| TW (1) | TW200538109A (xx) |
| WO (1) | WO2005082350A1 (xx) |
| ZA (1) | ZA200606679B (xx) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008283B2 (en) | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
| EP1603585A2 (en) * | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| AU2005311930B9 (en) | 2004-12-03 | 2009-09-10 | Merck Sharp & Dohme Corp. | Substituted piperazines as CB1 antagonists |
| CA2635261A1 (en) * | 2006-01-03 | 2007-07-12 | Algebra, Inc. | Therapeutic amine-arylsulfonamide conjugate compounds |
| KR20080097426A (ko) * | 2006-01-18 | 2008-11-05 | 쉐링 코포레이션 | 칸나비노이드 수용체 조절제 |
| WO2008052190A2 (en) * | 2006-10-26 | 2008-05-02 | Flynn Gary A | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
| WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| CN101790521A (zh) * | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
| CA2692268A1 (en) * | 2007-06-28 | 2009-01-08 | Intervet International B.V. | Substituted piperazines as cb1 antagonists |
| LT6401B (lt) * | 2015-07-28 | 2017-06-12 | Vilniaus Universitetas | Karboanhidrazės selektyvūs inhibitoriai |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3875150A (en) | 1969-04-29 | 1975-04-01 | Leo Pharm Prod Ltd | New sulfamyl-anthranilic acids |
| GB1260155A (en) * | 1969-04-29 | 1972-01-12 | Leo Pharm Prod Ltd | Sulphonamido anthranilic acid derivatives |
| DE2206424A1 (de) * | 1971-02-15 | 1972-08-24 | Dumex Ltd As | Verfahren zur Herstellung von N-substituierten Anthranilsäurederivaten |
| DE2247828A1 (de) * | 1972-09-29 | 1974-04-04 | Hoechst Ag | Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung |
| DE2406972C3 (de) * | 1974-02-14 | 1979-07-19 | Hoechst Ag, 6000 Frankfurt | Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren |
| DE2718871C3 (de) * | 1977-04-28 | 1980-07-17 | Hoechst Ag, 6000 Frankfurt | N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck |
| US4406896A (en) * | 1979-12-20 | 1983-09-27 | Merck & Co., Inc. | Adjuvants for rectal delivery of drug substances |
| DE3006686A1 (de) * | 1980-02-22 | 1981-08-27 | Hoechst Ag, 6000 Frankfurt | 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel |
| DE3041812A1 (de) * | 1980-11-06 | 1982-06-16 | Hoechst Ag, 6000 Frankfurt | Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel |
| DE3101960A1 (de) * | 1981-01-22 | 1982-09-02 | Hoechst Ag, 6000 Frankfurt | "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung" |
| US5256687A (en) * | 1985-09-09 | 1993-10-26 | Hoechst Aktiengesellschaft | Pharmaceutical composition for the treatment of high blood pressure |
| JPH0720862B2 (ja) * | 1989-01-27 | 1995-03-08 | ヘキスト・アクチエンゲゼルシヤフト | 吸入用喘息治療剤 |
| EP1007563A4 (en) * | 1997-06-12 | 2003-04-16 | Smithkline Beecham Corp | HM74A RECEPTOR |
| GB0021484D0 (en) * | 2000-09-01 | 2000-10-18 | Boehringer Ingelheim Pharma | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| DE10060809A1 (de) * | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker |
| US20030109673A1 (en) * | 2002-10-04 | 2003-06-12 | Xiao Yonghong | Regulation of human hm74-like g protein coupled receptor |
-
2005
- 2005-02-10 KR KR1020067016657A patent/KR20060127141A/ko not_active Application Discontinuation
- 2005-02-10 ME MEP-211/08A patent/MEP21108A/xx unknown
- 2005-02-10 RU RU2006133540/04A patent/RU2006133540A/ru not_active Application Discontinuation
- 2005-02-10 AU AU2005216879A patent/AU2005216879B2/en not_active Ceased
- 2005-02-10 RS RSP-2006/0473A patent/RS20060473A/sr unknown
- 2005-02-10 SG SG200901539-7A patent/SG164305A1/en unknown
- 2005-02-10 JP JP2006554129A patent/JP2007523166A/ja active Pending
- 2005-02-10 WO PCT/US2005/004108 patent/WO2005082350A1/en not_active Application Discontinuation
- 2005-02-10 MX MXPA06008612A patent/MXPA06008612A/es active IP Right Grant
- 2005-02-10 CN CNA2005800054570A patent/CN1921845A/zh active Pending
- 2005-02-10 BR BRPI0506792-8A patent/BRPI0506792A/pt not_active IP Right Cessation
- 2005-02-10 NZ NZ548830A patent/NZ548830A/en unknown
- 2005-02-10 EP EP05713210A patent/EP1718292A1/en not_active Withdrawn
- 2005-02-10 CA CA002557444A patent/CA2557444A1/en not_active Abandoned
- 2005-02-14 US US11/057,587 patent/US7232811B2/en not_active Expired - Fee Related
- 2005-02-18 TW TW094104731A patent/TW200538109A/zh unknown
- 2005-02-18 AR ARP050100596A patent/AR047747A1/es not_active Application Discontinuation
-
2006
- 2006-07-24 CR CR8528A patent/CR8528A/es not_active Application Discontinuation
- 2006-07-25 IL IL177086A patent/IL177086A/en not_active IP Right Cessation
- 2006-07-28 TN TNP2006000234A patent/TNSN06234A1/en unknown
- 2006-08-11 ZA ZA200606679A patent/ZA200606679B/xx unknown
- 2006-08-18 EC EC2006006777A patent/ECSP066777A/es unknown
- 2006-08-29 MA MA29295A patent/MA28373A1/fr unknown
- 2006-09-19 NO NO20064237A patent/NO20064237L/no not_active Application Discontinuation
-
2007
- 2007-05-07 US US11/745,131 patent/US7556931B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0506792A (pt) | 2007-05-22 |
| WO2005082350A8 (en) | 2005-12-08 |
| ECSP066777A (es) | 2006-11-16 |
| SG164305A1 (en) | 2010-09-29 |
| NO20064237L (no) | 2006-09-19 |
| IL177086A (en) | 2010-06-16 |
| IL177086A0 (en) | 2006-12-10 |
| MXPA06008612A (es) | 2007-01-25 |
| US20070213391A1 (en) | 2007-09-13 |
| AU2005216879A1 (en) | 2005-09-09 |
| ZA200606679B (en) | 2008-01-30 |
| US7556931B2 (en) | 2009-07-07 |
| CR8528A (es) | 2007-06-08 |
| AU2005216879B2 (en) | 2009-12-10 |
| NZ548830A (en) | 2010-03-26 |
| RU2006133540A (ru) | 2008-03-27 |
| KR20060127141A (ko) | 2006-12-11 |
| US20050187280A1 (en) | 2005-08-25 |
| JP2007523166A (ja) | 2007-08-16 |
| US7232811B2 (en) | 2007-06-19 |
| TNSN06234A1 (en) | 2007-12-03 |
| RS20060473A (xx) | 2008-08-07 |
| TW200538109A (en) | 2005-12-01 |
| CN1921845A (zh) | 2007-02-28 |
| CA2557444A1 (en) | 2005-09-09 |
| EP1718292A1 (en) | 2006-11-08 |
| AR047747A1 (es) | 2006-02-15 |
| MA28373A1 (fr) | 2006-12-01 |
| WO2005082350A1 (en) | 2005-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP21108A (en) | Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation | |
| DOP2019000287A (es) | Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) | |
| AU2016202535B2 (en) | Fused heterocyclic compounds as sodium channel modulators | |
| ATE524486T1 (de) | Lys-thr-dipeptide und deren verwendung | |
| MX2009011364A (es) | Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2-il) y n-(5-heteroarilcroman-3-il)carboxamida para el tratamiento del dolor. | |
| HK1138840A1 (en) | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
| BRPI0508464B8 (pt) | sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos | |
| NO20072895L (no) | Topiske sammensetninger inneholdende myrica gale olje | |
| EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
| ECSP11011082A (es) | Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos | |
| EA200970841A1 (ru) | Фармацевтическое применение замещенных амидов | |
| EA201390184A1 (ru) | Активирующие амрк гетероциклические соединения и способы их использования | |
| BRPI0721905B8 (pt) | composto inibidor de proteassoma, sua composição farmacêutica e seu uso | |
| EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
| SMT201200017B (it) | Nuovi antagonisti P2X7R e il loro uso. | |
| EA200700400A1 (ru) | Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии | |
| FR2968950B1 (fr) | Composition cosmetique comprenant un compose d'acide cucurbique | |
| ATE555116T1 (de) | Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie | |
| EA201170979A1 (ru) | Карбоксамидные соединения и способы их применения | |
| EA200901389A1 (ru) | Производные фталазина и изохинолина с модулирующим действием на s1p рецепторы | |
| CY1111588T1 (el) | Υποκατεστημενα καρβοξαμιδια ως ανταγωνιστες μεταβολοτροπου υποδοχεα ομαδας ι | |
| BRPI0508471A8 (pt) | compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos | |
| EA201200086A1 (ru) | Замещенные 2-карбоксамиды циклоаминомочевин | |
| NO20064214L (no) | Oxydecahydronaphthalen-modulatorer for HM74 |